These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38967794)

  • 1. Epigenetic regulation of DNA repair gene program by Hippo/YAP1-TET1 axis mediates sorafenib resistance in HCC.
    Mo C; You W; Rao Y; Lin Z; Wang S; He T; Shen H; Li X; Zhang R; Li B
    Cell Mol Life Sci; 2024 Jul; 81(1):284. PubMed ID: 38967794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of SSR2 Enhances Hepatocellular Carcinoma Cisplatin Sensitivity via the Hippo Pathway.
    Ye R; Yin L; Ge Y; Zhu X; Xiao Y; Fang C; Liu Q; Zhang H; Li H; Xie B
    Front Biosci (Landmark Ed); 2024 Aug; 29(8):299. PubMed ID: 39206890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
    Wu J; Chai H; Li F; Ren Q; Gu Y
    Life Sci; 2020 Nov; 260():118406. PubMed ID: 32918976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DEAD-Box Helicase 17 circRNA (circDDX17) Reduces Sorafenib Resistance and Tumorigenesis in Hepatocellular Carcinoma.
    Zhang X; Wang W; Mo S; Sun X
    Dig Dis Sci; 2024 Jun; 69(6):2096-2108. PubMed ID: 38653946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRNDE acts as an epigenetic modulator of the p300/YY1 complex to promote HCC progression and therapeutic resistance.
    Liu YC; Lin YH; Chi HC; Huang PS; Liao CJ; Liou YS; Lin CC; Yu CJ; Yeh CT; Huang YH; Lin KH
    Clin Epigenetics; 2022 Aug; 14(1):106. PubMed ID: 35999564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KAT6A is associated with sorafenib resistance and contributes to progression of hepatocellular carcinoma by targeting YAP.
    Jin Y; Yang R; Ding J; Zhu F; Zhu C; Xu Q; Cai J
    Biochem Biophys Res Commun; 2021 Dec; 585():185-190. PubMed ID: 34808502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRIM21 is critical in regulating hepatocellular carcinoma growth and response to therapy by altering the MST1/YAP pathway.
    Shu B; Zhou Y; Lei G; Peng Y; Ding C; Li Z; He C
    Cancer Sci; 2024 May; 115(5):1476-1491. PubMed ID: 38475938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silencing
    Zhu Q; Ren H; Li X; Qian B; Fan S; Hu F; Xu L; Zhai B
    Aging (Albany NY); 2020 Nov; 12(22):22975-23003. PubMed ID: 33203790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. METTL3 and METTL14-mediated N
    Wu X; Zeng M; Wei Y; Lu R; Huang Z; Huang L; Huang Y; Lu Y; Li W; Wei H; Pu J
    Sci Rep; 2024 Mar; 14(1):6155. PubMed ID: 38486042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA TTN-AS1 intensifies sorafenib resistance in hepatocellular carcinoma by sponging miR-16-5p and upregulation of cyclin E1.
    Zhou Y; Huang Y; Dai T; Hua Z; Xu J; Lin Y; Han L; Yue X; Ho L; Lu J; Ai X
    Biomed Pharmacother; 2021 Jan; 133():111030. PubMed ID: 33378944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma.
    Xia P; Zhang H; Xu K; Jiang X; Gao M; Wang G; Liu Y; Yao Y; Chen X; Ma W; Zhang Z; Yuan Y
    Cell Death Dis; 2021 Jul; 12(7):691. PubMed ID: 34244479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
    Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
    J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells.
    Zhou TY; Zhuang LH; Hu Y; Zhou YL; Lin WK; Wang DD; Wan ZQ; Chang LL; Chen Y; Ying MD; Chen ZB; Ye S; Lou JS; He QJ; Zhu H; Yang B
    Sci Rep; 2016 Aug; 6():30483. PubMed ID: 27476430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TET1 upregulation drives cancer cell growth through aberrant enhancer hydroxymethylation of HMGA2 in hepatocellular carcinoma.
    Shirai K; Nagae G; Seki M; Kudo Y; Kamio A; Hayashi A; Okabe A; Ota S; Tsutsumi S; Fujita T; Yamamoto S; Nakaki R; Kanki Y; Osawa T; Midorikawa Y; Tateishi K; Ichinose M; Aburatani H
    Cancer Sci; 2021 Jul; 112(7):2855-2869. PubMed ID: 33970549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GPAT3 is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma.
    Zhou Y; Zhao H; Ren R; Zhou M; Zhang J; Wu Z; Chen Y; Lei J; Chen Y; Yu Y; Li Y
    Theranostics; 2024; 14(9):3470-3485. PubMed ID: 38948063
    [No Abstract]   [Full Text] [Related]  

  • 16. Novel STAT3 oligonucleotide compounds suppress tumor growth and overcome the acquired resistance to sorafenib in hepatocellular carcinoma.
    Zhang QY; Ding W; Mo JS; Ou-Yang SM; Lin ZY; Peng KR; Liu GP; Lu JJ; Yue PB; Lei JP; Wang YD; Zhang XL
    Acta Pharmacol Sin; 2024 Aug; 45(8):1701-1714. PubMed ID: 38609562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the Hippo/YAP1 signaling pathway in hepatocellular carcinoma: From mechanisms to therapeutic drugs (Review).
    Li S; Hao L; Li N; Hu X; Yan H; Dai E; Shi X
    Int J Oncol; 2024 Sep; 65(3):. PubMed ID: 39092548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EPHB2 Activates β-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma.
    Leung HW; Leung CON; Lau EY; Chung KPS; Mok EH; Lei MML; Leung RWH; Tong M; Keng VW; Ma C; Zhao Q; Ng IOL; Ma S; Lee TK
    Cancer Res; 2021 Jun; 81(12):3229-3240. PubMed ID: 33903122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m
    Chen YT; Xiang D; Zhao XY; Chu XY
    Hum Cell; 2021 Nov; 34(6):1800-1811. PubMed ID: 34374933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.